Natco Pharma has informed that the Board of Directors at their meeting held on Wednesday, September 9, 2026, has considered and approved the following: Issuance of fully paid up equity shares of the Company of face value of ?2 each (Rights Equity Shares) for an amount not exceeding ?1,300 crore (Rupees One Thousand and Three Hundred Crore only) by way of a rights issue to the eligible equity shareholders of the Company, as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (SEBI ICDR Regulations”), subject to such regulatory and statutory approvals, as may be required under the applicable laws; Constitution of the Fund-Raising Committee of the Board with the following members and delegation of such powers as may be necessary to give effect to the Rights Issue: V.C. Nannapaneni, Chairman, Rajeev Nannapaneni, Member, Sri P.S.R.K. Prasad, Member.
The above information is a part of company’s filings submitted to BSE.
